Opinion|Videos|May 29, 2024
Novel Therapy + 5-Year Bladder Preservation for Patients with NMIBC
Author(s)Neal Shore, MD
A urologist discusses the prospective advantages of the novel gene therapy nadofaragene firadenovec compared to standard-of-care therapies for patients with BCG-unresponsive non-muscle-invasive bladder cancer (NMIBC) and highlights the significance of the reported 5-year bladder preservation and overall survival rates.
Advertisement
Episodes in this series
Video content above is prompted by the following question(s):
- What are the potential advantages of the novel gene therapy nadofaragenefiradenovec compared to standard-of-care therapies for patients with BCG-unresponsive NMIBC? Discuss the clinical significance of the 5-year bladder preservation and overall survival rates reported.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
CMS Final Rule Ends Federal Medicaid, CHIP Funding for Youth Gender-Affirming Care
2
Employers With Claims Data Access Take More Cost Action, Survey Finds
3
CAR T, Bispecifics Reshape Relapsed Lymphoma Care: Madhav Seshadri, MD
4
Site of Care, TDM Still Shape AYA ALL Outcomes: Emily K. Curran, MD
5